NCT00685373 - Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease | Biotech Hunter

Enrollment

166

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Cryopyrin-Associated Periodic SyndromesFamilial Cold Autoinflammatory SyndromeMuckle Wells SyndromeNeonatal Onset Multisystem Inflammatory Disease

Interventions

DRUG

Canakinumab (ACZ885)

6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.

Trial Locations (28)

31904

Allergy Center at Brookstone, Columbus

44195

Cleveland Clinic, Cleveland

53792

University of Wisconsin, Madison

60612

Rush-Presbyterian St. Lukes Medical Center, Chicago

72205

Little Rock Allergy and Asthma Clinic, Little Rock

94118

UCSF School of Medicine, San Francisco

Unknown

Novartis Investigative Site, Laken

Novartis Investigative Site, Le Kremlin-Bicêtre

Novartis Investigative Site, Lille

Novartis Investigative Site, Montpelier Cedex

Novartis Investigative site, Nantes

Novartis Investigative site, Berlin

Novartis Investigative Site, Hamburg

Novartis Investigative site, Heidelberg

Novartis Investigative Site, Herne

Novartis Investigative Site, Marburg

Novartis Investigative site, Tübingen

Novartis Investigative site, New Delhi

Novartis Investigative site, Genova

Novartis Investigative Site, Napoli

Novartis Investigative Site, Padua

Novartis Investigative Site, Rome

Novartis Investigative Site, Trieste

Novartis Investigative Site, Madrid

Novartis Investigative site, Oviedo

Novartis Investigative Site, Vigo

Novartis Investigative site, Istanbul

Novartis Investigative site, London